博来霉素A6对裸鼠移植的人体大肠癌的抑制作用

在裸鼠移植人结肠癌HT-29和人盲肠癌Hce-8693细胞,使用裸鼠可耐受的博来霉素A_6剂量,结果博来霉素A_6对肿瘤生长有明显的抑制作用,抑制率达90％左右。与等毒性剂量的5-氟脲嘧啶和丝裂霉素C比较,博来霉素A_6不仅对裸鼠移植的人结肠癌HT-29生长的抑制作用明显较强,且残存的非坏死肿瘤组织也较少。提示博来霉素A_6是一种对大肠癌有较强抗肿瘤活性的药物。

Inhibitory Effect of Bleom ycin A_6 on Human Colon Cancer Xenografts in Nude Mice

As evaluated by clonogenic assay, bleomycin A6 was found to be highly active against established human cancer cell lines derived from colon cancer (HT-29) and cecum cancer (Hce-8693). These human cancer cells have been serially transplanted in nude mice. At a tolerable dosage level, bleomycin A6 exerted remarkable growth inhibition on human colon cancer HT-29 and cecum cancer Hce-8693 xenografts (approximately 90% inhibition). No histopathological changes were found in the organs of treated animals. Compared on the basis of equitoxic doses (1/9 LD50), bleomycin A6 exerted much stronger growth inhibition against colon cancer HT-29 xenografts in nude mice than 5-fluorouracil and mitomycin C, with inhibition rates of 82%, 12% and 53%, respectively. More extensive necrosis was found in tumors treated with bleomycin A6 than in those treated with mitomycin C or 5-fluorouracil. The ratio values of non-necrotic tumor tissue to whole tumor tissue for bleomycin A6, mitomycin C and 5-fluorouracil were 0.33, 0.65 and 0.57, respectively. These observations indicate that bleomycin A6 is a potent antitumor agent against colon cancer xenografts and may be useful in human colon cancer chemotherapy.